Abstract
Objectives
The research aimed to study the following questions: (1) five well-known gout-related medications were selected to test the validity of the prescription symmetry sequence analysis in Taiwan; (2) four exploratory medications were selected to test their relation to gout flares.
Methods
We utilized the 2003–2017 dataset of the Taiwan National Health Insurance Program containing all claims data with 2 million beneficiaries as a data source. In order to explore the temporal association, we designed a scenario of medication-induced gout flares. Nine medications were selected as the index agent, including aspirin (low-dose), thiazide diuretics, loop diuretics, ethambutol, pyrazinamide, metformin, pioglitazone, fenofibrate, and losartan. The gout flare was defined as subjects with use of the marker agent for treatment of gout flares. The observation-window period between initiation of the index agent and initiation of the marker agent was 1 year. Subjects who used an index agent and a marker agent on the same day were excluded. The prescription symmetry sequence analysis was carried out to compare the observed number of persons who took an index agent prior to starting a marker agent with the observed number of persons who took a marker agent before starting an index agent. The adjusted sequence ratio (adjusted SR) with 95% confidence interval was applied to estimate the relation between an index agent and the marker agent.
Results
Among five medications including aspirin (low-dose), thiazide diuretics, loop diuretics, ethambutol, and pyrazinamide, the adjusted sequence ratio ranged from 1.15 to 3.35 and all reached statistical significance. Fenofibrate use and losartan use were associated with a lower probability of gout flares, with reaching statistical significance (adjusted SR = 0.60 for fenofibrate and adjusted SR = 0.92 for losartan). Metformin use was associated with a greater probability of gout flares, with reaching statistical significance (adjusted SR = 1.14). Pioglitazone use did not reach statistical significance.
Conclusion
Based on the confirmatory analysis including five well-known gout-related medications, this study supports that the prescription symmetry sequence analysis can be used to detect an adverse drug event associated with one potential offending agent. The exposure to fenofibrate or losartan might be a protective factor against gout flares. Metformin use could be associated with a greater probability of gout flares, but this finding should be validated by other studies.
Key Points: • What is already known about this subject? 1. The prescription symmetry sequence analysis is a useful method for detecting an adverse drug reaction associated with one potential offending drug. 2. Numerous medications are found to induce gout flares. • What does this study add? 1. The prescription symmetry sequence analysis supports the evidence that aspirin (low-dose), thiazide diuretics, loop diuretics, ethambutol and pyrazinamide are associated with a greater probability of gout flares. 2. The exposure to fenofibrate or losartan might be a protective factor against gout flares. 3. Metformin use could be associated with a greater probability of gout flares. • How might this impact on clinical practice or future developments? 1. Clinicians should always consider the possibility of medication-induced gout flares. If gout flares develop, discontinuation of risky medications is the first step. Then prescribing cascades can be eliminated. |
Similar content being viewed by others
Data availability
The datasets used and/or analyzed during the current study is available from the corresponding author on reasonable request.
References
Petri H, de Vet HC, Naus J, Urquhart J (1988) Prescription sequence analysis: a new and fast method for assessing certain adverse reactions of prescription drugs in large populations. Stat Med 7:1171–1175
Hallas J (1996) Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology 7:478–484
Lai EC, Pratt N, Hsieh CY, Lin SJ, Pottegård A, Roughead EE et al (2017) Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies. Eur J Epidemiol 32:567–582
Morris EJ, Hollmann J, Hofer AK, Bhagwandass H, Oueini R, Adkins LE et al (2022) Evaluating the use of prescription sequence symmetry analysis as a pharmacovigilance tool: a scoping review. Res Social Adm Pharm 18:3079–3093
Chen Y, Huang ST, Hsu TC, Peng LN, Hsiao FY, Chen LK (2022) Detecting suspected prescribing cascades by prescription sequence symmetry analysis of nationwide real-world data. J Am Med Dir Assoc 23:468–474
Dalbeth N, Gosling AL, Gaffo A, Abhishek A (2021) Gout Lancet 397:1843–1855
Mikuls TR (2022) Gout. N Engl J Med 387:1877–1887
Scott JT (1991) Drug-induced gout. Baillieres Clin Rheumatol 5:39–60
Ben Salem C, Slim R, Fathallah N, Hmouda H (2017) Drug-induced hyperuricaemia and gout. Rheumatology (Oxford) 56:679–688
Tsiropoulos I, Andersen M, Hallas J (2009) Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis. Pharmacoepidemiol Drug Saf 18:483–491
Waldman B, Ansquer JC, Sullivan DR, Jenkins AJ, McGill N, Buizen L et al (2018) Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. Lancet Diabetes Endocrinol 6:310–318
Würzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR et al (2001) Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 19:1855–1860
FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM et al (2020) 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken) 72:744–760
Lund LC, Højlund M, Henriksen DP, Hallas J, Kristensen KB (2021) Sodium-glucose cotransporter-2 inhibitors and the risk of gout: a Danish population based cohort study and symmetry analysis. Pharmacoepidemiol Drug Saf 30:1391–1395
Wood DT, Waterbury NV, Lund BC (2023) Sodium glucose cotransporter 2 inhibitors and gout risk: a sequence symmetry analysis. Clin Rheumatol 42:2469–2475
Hu JR, Yeh HC, Mueller NT, Appel LJ, Miller ER 3rd, Maruthur NM et al (2021) Effects of a behavioral weight loss intervention and metformin treatment on serum urate: results from a randomized clinical trial. Nutrients 13:2673
Niu SW, Chang KT, Lin HY, Kuo IC, Chang YH, Chen YH et al (2018) Decreased incidence of gout in diabetic patients using pioglitazone. Rheumatology (Oxford) 57:92–99
Kutoh E, Hori T (2013) Effect of pioglitazone on serum uric acid levels in newly diagnosed, drug-naïve patients with type 2 diabetes. Endocr Res 38:151–159
Wahab IA, Pratt NL, Wiese MD, Kalisch LM, Roughead EE (2013) The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection. Pharmacoepidemiol Drug Saf 22:496–502
Author information
Authors and Affiliations
Contributions
Shih-Wei Lai contributed to the conception of the article, initiated the draft of the article, and approved the final draft. Yu-Hung Kuo and Kuan-Fu Liao conducted data analysis. Bing-Fang Hwang and Chiu-Shong Liu interpreted the data and contributed equally to the article.
Corresponding author
Ethics declarations
Disclosures
None.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Lai, SW., Hwang, BF., Kuo, YH. et al. Risk of gout flare after medication: prescription symmetry sequence analysis. Clin Rheumatol 43, 1183–1188 (2024). https://doi.org/10.1007/s10067-024-06891-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-024-06891-x